Reduced adrenal stress response in patients on PCSK9 inhibitor therapy

Treatment with proprotein convertase subtilisin-kexin type 9 inhibitors (PCSK9i), in addition to statin therapy, reduces LDL-cholesterol (LDL-c) in some patients to extremely low levels (i.e.

Source: Atherosclerosis - March 30, 2021 Category: Cardiology Authors: S. Meier, M. Frick, M. Liu, S.S. Saeedi Saravi, G. Montrasio, H. Preiss, L. Pasterk, N. Bonetti, M. Egloff, H.R. Schmid, I. Sudano, G.G. Camici, F. Mach, T.F. Luescher, G. Ehret, J.H. Beer Source Type: research